window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 5, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Monocyte Cell Therapy

  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain,Therapeutic Areas

    eXmoor and Signadori Bio partner to advance monocyte-based cell therapy for solid tumours

    New alliance focuses on translation, process development and GMP-readiness for [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Aravax’s PVX108 wins FDA Fast Track designation for peanut allergy
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Medicus Pharma gets UAE approval to start genomics-guided endometriosis study
    Categories: Clinical & Regulatory, Drug Discovery & Development, Genomics and sequencing, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • First UK patient dosed in personalised lung cancer vaccine trial using Touchlight DNA technology
    Categories: Advanced Therapies, Clinical & Regulatory, Manufacturing & Supply Chain, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top